International review of movement disorders, Journal Year: 2024, Volume and Issue: unknown, P. 63 - 79
Published: Jan. 1, 2024
Neurology and Therapy, Journal Year: 2024, Volume and Issue: 13(4), P. 1055 - 1068
Published: June 14, 2024
The management of Parkinson's disease (PD) continues to evolve with advancements in non-oral levodopa-based therapies aiming provide continuous drug delivery (CDD). Such address the challenges posed by emergence motor fluctuations, dyskinesias, and non-motor fluctuations (NMF) associated oral levodopa administration contributing define advanced stage PD. key focus this review is placed on subcutaneous foslevodopa/foscarbidopa (Foslevodopa/foscarbidopa) infusion, showcasing its recent clinical availability efficacy providing delivery. While an overview other CDD systems, such as intrajejunal levodopa–carbidopa infusion levodopa–entacapone–carbidopa we highlight current promising evidence for Foslevodopa/foscarbidopa improve, example, "on time" without troublesome dyskinesia reducing "off people Additionally, demonstrates potential managing early morning off periods, sleep quality symptoms. Moreover, options ND0612 DIZ102/DIZ101 are discussed, their pharmacokinetics/pharmacodynamics, efficacy, safety profiles. these present new therapeutic avenues, long-term observational studies warranted elucidate impact existing PD therapies. Overall, provides insights into evolving landscape offers a pragmatic approach integration practice.
Language: Английский
Citations
8
Current Opinion in Neurology, Journal Year: 2024, Volume and Issue: 37(4), P. 409 - 413
Published: May 23, 2024
Purpose of review to recent progress in the development and use continuous levodopa therapies Parkinson disease (PD). Recent findings Levodopa/Carbidopa intestinal gel (LCIG) is a therapy which widely used United States, Europe other countries effective at reducing ‘off’ time. work has shown that LCIG can be useful managing dyskinesias improve nonmotor symptoms quality life. Several studies have good long-term effectiveness LCIG. data support cost-effectiveness this treatment strategy. Subcutaneous (SC) delivery newer strategy avoids need for surgically placed gastric tube. Two different products enabling SC are development: ND0612 foslevodopa/foscarbidopa. Both recently been reduce time randomized, double-blind trials. Adverse effects primarily related skin reactions infusion site. Summary Continuous treat motor fluctuations cannot managed with standard oral therapies. They may also symptoms, overall life patients advanced PD.
Language: Английский
Citations
5
Neurologic Clinics, Journal Year: 2025, Volume and Issue: 43(2), P. 383 - 397
Published: Jan. 22, 2025
Language: Английский
Citations
0
CNS Drugs, Journal Year: 2025, Volume and Issue: unknown
Published: April 8, 2025
Language: Английский
Citations
0
Expert Review of Medical Devices, Journal Year: 2025, Volume and Issue: unknown
Published: May 7, 2025
Device-aided therapies (DATs) have been developed to provide continuous drug delivery (CDD) people with advanced Parkinson's disease (PD) whose symptoms can no longer be effectively managed oral or transdermal therapy. Intrajejunal infusion of levodopa - carbidopa intestinal gel (LCIG), delivered via the CADD Legacy 1400 pump, is an established CDD option, while entacapone (LECIG), Crono LECIG a more recent addition range DAT options in Europe. This article explores rationale for development infusion, role formulation, and attributes specifications pump device. Clinical real-world data reporting its efficacy, safety tolerability PD patients from European centers are reviewed, focus on practical benefits that smaller, lighter quieter device who wish start treatment intrajejunal infusion. offers another valuable option consider suitable providing both good long-term clinical favorable experience patients.
Language: Английский
Citations
0
International review of movement disorders, Journal Year: 2024, Volume and Issue: unknown, P. 63 - 79
Published: Jan. 1, 2024
Citations
0